mao-b

AChE BChE MAO-B-IN-1 is a reversible, non-time-dependent inhibitor of AChE, BChE, and MAO-B that crosses the blood-brain barrier, exhibiting inhibitory effects on hAChE, hBChE, and hMAO-B with IC50s of 7.31, 0.56, and 26.1 μM, respectively. [AChE BChE MAO-B-IN-1] had a neuroprotective effect and was not significantly cytotoxic.

hMAO-B-IN-32 is a potent hMAO-B selective inhibitor with an IC50 of 45.52 μM.

Sembragiline (EVT-302) is a selective MAO-B inhibitor for the study of Alzheimer's disease (AD).

Ladostigil (Ladostigil free base) is an orally active dual inhibitor of cholinesterase and brain-selective monoamine oxidase (MAO) with inhibitory effects on MAO-B and AChE, with IC50 values of 37.1 and 31.8 μM, respectively.Ladostigil possesses anti-inflammatory, antioxidant, and neuroprotective activities, and may be used in studies of depression and Alzheimer's disease.

Femoxetine is a 5-HT inhibitor with antidepressant activity that potentiates morphine-induced anti-injury feelings and inhibits MAO-A and MAO-B required for the production of high exercise capacity in mice.

Atibeprone is a MAO-B inhibitor with antidepressant activity for the study of Parkinson's disease.

Pargyline (Pargylamine) is a monoamine oxidase inhibitor with antihypertensive properties.

Tedizolid (DA-7157)is a novel oxazolidinone-class antibiotic that inhibits bacterial protein synthesis by binding to the 23S ribosomal RNA of the 50S subunit of the ribosome.

Paeonol (Peonol) is an active extraction from Paeonia suffruticosa. Paeonol inhibits MAO-A and MAO-B with IC50 of 54.6 μM and 42.5 μM, respectively.

Rasagiline Mesylate (AGN1135) is a novel MAO-B inhibitor, which can treat idiopathic Parkinson's disease.

CHBO4 is an hMAO-B inhibitor that is potent, reversible, competitive and selective.The IC50 value of CHBO4 against hMAO-B in the CHBO assay was 0.031 μM, and the Ki value was 0.010 ± 0.005 μM.CHBO4 reduces cellular damage by scavenging intracellular reactive oxygen species (ROS), and can be used to study Parkinson's disease (PD).

Vafidemstat (ORY-2001) is a selective, orally active lysyl-histone demethylase (LSD1) MAO-B inhibitor that crosses the blood-brain barrier for the study of neurological diseases.

Bifemelane hydrochloride is a MAO inhibitor

Selegiline hydrochloride is a selective, reversible inhibitor of MAO-B (Ki = 0.091 μM) over MAO-A (Ki = 9.06 μM). Monoamine oxidase (MAO) inhibitors have utility in ameliorating a variety of neurological conditions, including depression.

MAO-B-IN-5 is a potent, selective, and orally active MAO-B inhibitor with an IC50 of 0.204 μM, showing potential for research in Parkinson's disease (PD) [1].

MAO-B-IN-1 is a monoamine oxidase B inhibitor and can be used for the research of neurological diseases.

MAO-B-IN-8 is a highly potent and reversible inhibitor of monoamine oxidase-B (MAO-B), also inhibiting microglial production of neuroinflammatory mediators. This compound is specifically designed for research on neurodegenerative diseases [1].

MAO-B-IN-2 is a selective and competitive inhibitor of MAO-B and BChE with IC50 values of 0.51 μM and 7.00 μM, respectively. It attenuates H2O2-induced cellular damage due to its strong ROS scavenging properties.

MAO-B-IN-34 (compound 3d) is an inhibitor of monoamine oxidase B.

MAO-B-IN-36 (Compound A6) is an effective MAO-B inhibitor with an IC50 of 13 nM.

C5 is a highly efficient and selective MAO-B inhibitor.

MAO-B-IN-37 (Compound 37) is a derivative of TT01001 and acts as a selective inhibitor of monoamine oxidase B (MAO-B), with an IC50 of 270 nM. It exhibits good metabolic stability in mouse microsomes and shows strong affinity for human serum albumin.

MAO-B-IN-38 (Compound 6b) is a reversible, competitive inhibitor of MAO-B, exhibiting IC50 values of 0.03 µM for MAO-B and 21.46 µM for MAO-A. This compound is applicable in research on neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.

AChE MAO-B-IN-7 (VAV-8) is a compound that acts as a dual inhibitor of acetylcholinesterase (AChE) and MAO-B, with the ability to cross the blood-brain barrier. It also inhibits the aggregation of Aβ42, making it a valuable compound for Alzheimer's disease (AD) research.